Articles published by UroGen Pharma Ltd.
UroGen Pharma Reports Third Quarter 2023 Financial Results
November 14, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
November 13, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 03, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
August 31, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
August 10, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 02, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
March 09, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
March 01, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
February 15, 2023
From UroGen Pharma Ltd.
Via Business Wire
Tickers
URGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.